touchHAEMATOLOGY touchHAEMATOLOGY
Myelodysplastic Syndrome
Watch Time: 11 mins

IMerge Phase 3 study – Imetelstat achieving RBC-TI in lower-risk myelodysplastic syndromes: Rami Komrokji, ASH 2023

Copy Link
Published Online: Dec 20th 2023

The IMerge Phase 3 study (NCT02598661) is a phase 2/3 global study investigating imetelstat, a first-in-class telomerase inhibitor, for patients with red blood cell transfusion-dependent non-del(5q) lower risk-myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis-stimulating agents (ESAs). We were joined by Dr Rami Komrokji (Moffitt Cancer Center, Tampa, FL, USA) to discuss the unmet needs in LR-MDS treatment, the unique methodology of the IMerge Phase 3 study and the different risk subgroups, its impact on red blood cell transfusion independence, and the factors contributing to suboptimal LR-MDS outcomes. Dr Komrokji also explored the potential clinical impact of the IMerge Phase 3 study findings, offering insights into future treatment paradigms.

The abstract entitled “Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study” was presented at the 65th ASH Annual Meeting and Exposition December 9-12, 2023, in San Diego, CA, USA.

Questions

  1. What are the unmet needs in the treatment of lower-risk Myelodysplastic Syndromes (LR-MDS) that are relapsed/refractory to Erythropoiesis-Stimulating Agents (ESAs)? (0:13)
  2. What was unique about the methodology of the IMerge Phase 3 study in assessing the efficacy of imetelstat for achieving Red Blood Cell Transfusion Independence (RBC-TI) across different risk subgroups in LR-MDS patients? (3:03)
  3. What were the primary and secondary endpoints and how well were they achieved? (4:28)
  4. What factors are known to cause suboptimal outcomes in the treatment of LR-MDS, and how does imetelstat address these factors? (6:56)
  5. What will be the likely clinical impact of the findings from the IMerge Phase 3 study in LR-MDS patients relapsed/refractory to ESAs? (9:08)

Disclosures: Rami Komrokji has received honoraria, has a membership on an entity’s Board of Directors or advisory committees, and is part of a Speakers Bureau for AbbVie, CTI biopharma, Jazz, Pharma Essentia, and Servio; has received consultancy fees from Geron; has received honoraria, has a membership on an entity’s Board of Directors or advisory committees, and received research funding from BMS; has received honoraria, has a membership on an entity’s Board of Directors or advisory committees for Rigel, Taiho, and DSI; and has a membership on an entity’s Board of Directors or advisory committees for Novartis.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of the ASH 2023

Click here for more content on myelodysplastic syndromes

Share this Video
Related Videos In Myelodysplastic Syndrome
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72